2026年3月,Cerus内部人出售了380 000多股股份,将股息减少8.6%至11.6%,因为股票关闭时股价为1.80美元。 In March 2026, Cerus insiders sold over 380,000 shares, reducing stakes by 8.6% to 11.6%, as stock closed at $1.80.

2026年3月12日, Cerus Corporation Interneters 总共出售了380,000多股股份,其中包括COO Vivek Jayaraman的165,200股,平均价格为每股1.66美元,共计约630,000美元。 On March 12, 2026, Cerus Corporation insiders sold a combined total of over 380,000 shares, including 165,200 by COO Vivek Jayaraman, at an average price of $1.66 per share, totaling approximately $630,000. 3月15日,该公司的股票结存为1.80美元,因此,销售量减少了8.6%,减至11.6%。 The sales reduced their stakes by 8.6% to 11.6%, with the company’s stock closing at $1.80 on March 15. Cerus于3月2日报告了Q4收入,达到预期,每股损失1美元,收入超过估计数6 458万美元。 Cerus reported Q4 earnings on March 2, meeting expectations with a $0.01 loss per share and $64.58 million in revenue, above estimates. 该生物技术公司通过其InterCEBT血液系统专注于血液安全,其市场上限为3.4591亿美元,具有混合分析师评级,并提出了协商一致的“减价”建议。 The biotech firm, focused on blood safety via its INTERCEPT Blood System, has a market cap of $345.91 million and a mixed analyst rating, with a consensus "Reduce" recommendation.